ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 3095

Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study

Suzanne C. Li1, Kathryn S. Torok2, Sandy D. Hong3, Polly J. Ferguson4, C. Egla Rabinovich5, Mara L Becker6, Fatma Dedeoglu7, Maria F. Ibarra8, Robert C. Fuhlbrigge9,10, Katie G. Stewart11, Marilynn G. Punaro11, Thomas Mason II12, Elena Pope13, Ronald Laxer14, Gloria C. Higgins15,16 and Brian Feldman17, 1Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 2Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, 4Dept of Pediatrics--Rheum, University of Iowa, Iowa City, IA, 5Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, 6Rheumatology, Children's Mercy Kansas City, Kansas City, MO, 7Rheumatology, Boston Children's Hospital, Boston, MA, 8Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, 9Program in Rheumatology, Division of Immunology, Boston Children’s Hospital, Boston, MA, 10Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 11Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, 12Rheumatology, Mayo Clinic, Rochester, MN, 13Dermatology, Hospital for Sick Children, Toronto, ON, Canada, 14Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 15Pediatric Rheumatology OSU, Nationwide Childrens Hosp, Columbus, OH, 16Pediatric Rheumatology Ohio State University, Nationwide Childrens Hospital, Columbus, OH, 17Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Comparative effectiveness and harms, Morphea, Pediatric rheumatology, scleroderma and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:   Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease that causes severe morbidity, including growth defects, cosmetic deformities, seizures and arthropathy. Optimal therapy is not known. The LS Children’s Arthritis and Rheumatology Research Alliance (CARRA) subgroup has been working towards conducting comparative effectiveness studies with the aim of improving long-term outcome. We report our initial findings from a pilot study to evaluate the feasibility of conducting such studies.

Methods:    

We conducted a multi-center 12 month prospective observational cohort study of jLS subjects treated with one of 3 methotrexate (MTX)-based standardized treatment regimens (consensus treatment plans, CTPs), chosen by the treating physician. Each CTP included MTX administered for 1 year; two included corticosteroids (CS), either intravenous (IV) for 3 months or oral for 48 weeks (tapering schedule).  The CTP options are based upon best available evidence and reflect the current treatment practices of CARRA members  (Li et al., Arthritis Rheum 2012; 64:1175).  Data were entered into a web-based registry (InForm), including activity and damage assessments, global assessments (GA), adverse events (AE), and medications. 

Results:

The target enrollment (50 subjects) was reached. Median age at enrollment was 13 years, majority of subjects were Caucasian (92%), female (70%), had the linear subtype (82%) and had never been treated with MTX or CS (82%). Fourty percent of subjects had a head lesion, 72% had extracutaneous involvement.

            Participating sites showed strong CTP preferences, with 50% choosing only 1 and 40% 2 CTPs. Half the subjects were enrolled into MTX + IV CS, 14 into MTX alone, and 11 into MTX + oral CS CTPs. Ninety percent of subjects were followed for at least 6 months, 80% completed the full 12 months.

            Among subjects followed for at least 6 months, 49% were considered to have a major and 31% a moderate improvement in activity level compared to baseline. Subjects in the MTX + CS CTPs were more likely than those in the MTX alone CTP to be rated as having a major improvement (57% vs 22%). Thirty two percent of subjects had a major deviation from their starting CTP with the most common reasons being AE (28%) and lack of response (28%). The AEs most commonly associated with deviations were severe gastrointestinal symptoms, mood issues, and infections. There was 1 SAE: one subject required hospitalization for viral gastroenteritis. Mycophenolate mofetil and/or IV CS were the most commonly employed therapies when there was a lack of response.   Subjects that deviated from initial CTP had a higher physician GA of disease activity and patient/parent GA of disease impact at baseline compared to those that did not. 

Conclusion:   Our pilot study shows the feasibility of conducting jLS comparative effectiveness studies across multiple centers. Despite a high rate of deviation from the CTPs, the majority of subjects were rated as having moderate or major improvement. Centers showed strong biases in their treatment preferences highlighting the need to have sufficient site variability and CTPs to enable comparative effectiveness studies.

Funded by Arthritis Foundation, DCRI, NIAMS, and Friends of CARRA


Disclosure: S. C. Li, None; K. S. Torok, None; S. D. Hong, None; P. J. Ferguson, None; C. E. Rabinovich, Abbie Vie, 2,UCB Pharma, 2,Hoffmann-La Roche Inc., 2,Janssen Research & Development, LLC, 2; M. L. Becker, None; F. Dedeoglu, None; M. F. Ibarra, None; R. C. Fuhlbrigge, None; K. G. Stewart, None; M. G. Punaro, None; T. Mason II, None; E. Pope, None; R. Laxer, None; G. C. Higgins, None; B. Feldman, None.

To cite this abstract in AMA style:

Li SC, Torok KS, Hong SD, Ferguson PJ, Rabinovich CE, Becker ML, Dedeoglu F, Ibarra MF, Fuhlbrigge RC, Stewart KG, Punaro MG, Mason T II, Pope E, Laxer R, Higgins GC, Feldman B. Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/initial-results-of-a-pilot-juvenile-localized-scleroderma-jls-comparative-effectiveness-study/. Accessed May 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/initial-results-of-a-pilot-juvenile-localized-scleroderma-jls-comparative-effectiveness-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.